CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 5, June 2013
AFRICA
179
Best Prac Res Clin Obstet Gynaecol
2008;
22
: 559–567.
12. Fourie C, Rooyen JV, Pieters M, Conradie K, Hoekstra T, Schutte A. Is
HIV-1 infection associated with endothelial dysfunction in a popula-
tion of African ancestry in South Africa?
Cardiovasc J Afr
2011;
22
:
134–140.
13. Mahmoud F, Omu A, Abul H, El-Rayes S, Haines D. Lymphocyte
subpopulations in pregnancy complicated by hypertension.
J Obstet
Gynaecol
2003;
23
: 20–26.
14. Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, McG
Thom SA, Hughes AD,
et al
. Pre-eclampsia,antiretro viral therapy, and
immune reconstitution.
Lancet
2002;
360
: 1152–1154.
15. De Groot MR, Corporaal LJ, Cronje HS, Joubert G. HIV infection in
critically ill obstetrical patients.
Int J Gynaecol Obstet
2003;
81
: 9–16.
16. Mattar R, Amed AM, Lindsey PC, Sass N, Daher S. Preeclampsia and
HIV infection.
Eur J Obstet Gynecol Reprod Biol
2004;
117
: 240–241.
17. Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble
fms-like tyrosine kinase-1 and placental growth factor: current knowl-
edge, clinical implications and future application. E
ur J Obstet Gynecol
Reprod Biol
2010;
151
: 122–129.
18. Suy A, Martinez E, Coll O, Lonca M, Palacio M, de Lazzari E,
et al
.
Increased risk of pre-eclampsia and fetal death in HIV-infected preg-
nant women receiving highly active antiretroviral therapy.
AIDS
2006;
20
: 59–66.
19. Frank KA, Buchmann EJ, Schackis RC. Does human immunodefi-
ciency virus infection protect against preeclampsia–eclampsia?
Obstet
Gynecol
2004;
104
: 238–242.
20. Eskild A, Vatten L. Do pregnancies with pre-eclampsia have smaller
placentas? A population study of 317 688 pregnancies with and without
growth restriction in the offspring.
Br J Obstet Gynaecol
2010;
117
:
1521–1526.
21. Levine RJ, Lam C, Qian C, Hu KF, Maynard SE, Sachs BP,
et al
.
Soluble endoglin and other circulating antiangiogenic factors in preec-
lampsia.
New Engl J Med
2006;
355
: 992–1005.
22. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi S, Lim KH.
Diagnostic utility of soluble fmslike tyrosine kinase 1 and soluble
endoglin in hypertensive diseases of pregnancy.
Am J Obstet Gynecol
2007;
197
: 28.e1–e6.
23. Levine R, Karamanchi S. Circulating angiogenic factors in preeclamp-
sia.
Clin Obstet Gynecol
2005;
48
: 372–386.
24. Ferrara N, Keyt B. Vascular endothelial growth factor: Basic biology
and clinical implications.
EXS J
1997;
79
: 209–232.
25. Ferrara N. Vascular endothelial growth factor: Basic science and clini-
cal progress.
Endocrinol Rev
2004;
25
: 581–611.
26. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth
factor.
Endocrinol Rev
1997;
18
: 4–25.
27. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S,
et al
. Excess
placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to
endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
J Clin Invest
2003;
111
: 649–658.
28. Lebrin F, Deckers M, Bertolino P, Dijke Pt. TGF-beta receptor function
in the endothelium.
Cardiovasc Res
2005;
65
: 599–608.
29. Lim JH, Kim SY, SoYeonPark, Lee MH, Yang JH, Kim MY,
et al.
Soluble endoglin and transforming growth factor-
β
1in women who
subsequently developed preeclampsia.
Prenat Diagn
2009;
29
(5):
471–476.
30. Lyall F. Priming and Remodelling of Human Placental Bed Spiral
Arteries During Pregnancy – A Review.
Placenta
2005;
26
(Suppl A)
Trophoblast Res
19
: S31–S6.
31. Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine
kinase (sFlt) receptor as a pre-eclampsia molecule.
Nephrol Dial
Transplant
2006;
21
: 3052–3054.
32. Lopez-Novoa JM. Soluble endoglin is an accurate predictor and a
pathogenic molecule in pre-eclampsia.
Nephrol Dial Transplant
2007;
22
(3): 712–714.
33. Maynard S, Epstein F, Karamanchi SA. Preeclampsia and angiogenic
imbalance.
Ann Rev Med
2008;
59
: 61–78.
34. Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA. Soluble
Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogen-
esis of preeclampsia.
Pediatr Res
2005;
57
: 1R–7R.
35. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, KimYM,
et
al
. Soluble endoglin contributes to the pathogenesis of preeclampsia.
Nat Med
2006;
12
: 642–649.
36. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating
concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and
maternal serum during pre-eclampsia.
Eur J Obstet Gynecol Reprod
Biol
2005;
122
: 33–39.
37. Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W.
Evaluation of placenta growth factor and soluble Fms-like tyrosine
kinase 1 receptor levels in mild and severe preeclampsia.
Am J Obstet
Gynecol
2006;
195
: 255–259.
38. Simas TAM, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard
SE. Angiogenic factors for the prediction of preeclampsia in high-risk
women.
Am J Obstet Gynecol
2007;
197
: 244e1–e8.
39. Vivo AD, Baviera G, Giordano D, Todarello G, Corrado F, D’Anna R.
Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia.
A
cta Obstet Gynecol
2008;
87
: 837–842.
40. Djurovic S, Schjetlein R, Wisloff F, Haugen G, Husby H, Berg K.
Plasma concentrations of Lp (a) lipoprotein and TGF-beta 1 are altered
in preeclampsia.
Clin Genet
1997;
52
: 371–376.
41. Huber A, Hefler L, Tempfer C, Zeisler H, Lebrecht A, Husslein P.
Transforming growth factor-beta 1 serum levels in pregnancy and
preeclampsia.
Acta Obstet Gynecol Scand
2002;
81
: 168–171.
